Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F13%3A10191978" target="_blank" >RIV/00216208:11110/13:10191978 - isvavai.cz</a>
Result on the web
<a href="http://dx.doi.org/10.1056/NEJMoa1213917" target="_blank" >http://dx.doi.org/10.1056/NEJMoa1213917</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1056/NEJMoa1213917" target="_blank" >10.1056/NEJMoa1213917</a>

Result language
angličtina
Original language name
Macitentan and Morbidity and Mortality in Pulmonary Arterial Hypertension
Original language description
Background Current therapies for pulmonary arterial hypertension have been adopted on the basis of short-term trials with exercise capacity as the primary end point. We assessed the efficacy of macitentan, a new dual endothelin-receptor antagonist, usinga primary end point of morbidity and mortality in a long-term trial. Methods We randomly assigned patients with symptomatic pulmonary arterial hypertension to receive placebo once daily, macitentan at a once-daily dose of 3 mg, or macitentan at a once-daily dose of 10 mg. Stable use of oral or inhaled therapy for pulmonary arterial hypertension, other than endothelin-receptor antagonists, was allowed at study entry.
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FA - Cardiovascular diseases including cardio-surgery
OECD FORD branch
—

Publication year
2013
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)